Patupilone
- Generic Name
- Patupilone
- Drug Type
- Small Molecule
- Chemical Formula
- C27H41NO6S
- CAS Number
- 152044-54-7
- Unique Ingredient Identifier
- UEC0H0URSE
- Background
Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.
- Indication
Investigated for use/treatment in ovarian cancer, lung cancer, brain cancer, breast cancer, and gastric cancer.
Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma
- Conditions
- Recurrent Glioblastoma Planned for Reoperation
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2011-09-15
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 9
- Registration Number
- NCT00715013
Phase I Study of Patupilone and RAD001
- Conditions
- Refractory Malignancy
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-06-14
- Target Recruit Count
- 42
- Registration Number
- NCT00496600
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
- Conditions
- Advanced Malignancies
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT00468260
Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT00448396
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00442741
Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00426582
- Locations
- 🇺🇸
Wertz Clinical Cancer Center (Wayne State University), Detroit, Michigan, United States
🇺🇸Cancer Research and Treatment Center (University of New Mexico), Albuquerque, New Mexico, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT00426140
- Locations
- 🇺🇸
Cancer Therapy and Research Center, Institution for Drug Development, San Antonio, Texas, United States
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00420615
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2010-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00412789
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
- Conditions
- Metastatic Hormone Refractory Prostate Cancer
- Interventions
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 185
- Registration Number
- NCT00411528
- Locations
- 🇺🇸
University of Colorado Dept. of Univ. of Colorado, Aurora, Colorado, United States
🇺🇸University of California San Diego Dept of Moores Cancer Center, La Jolla, California, United States
🇺🇸Norwalk Hospital, Norwalk, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.